Assembly Biosciences, Inc. (ASMB)
ASMB moved a median of -0.01% 30 minutes after news, and -0.08% by the close. How ASMB actually reacts to news — the realized, point-in-time move the market made, measured across 236 labeled events over the last three years with zero look-ahead.
ASMB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 212 |
| 30-min | -0.01% | 41% | 227 |
| 60-min | -0.55% | 42% | 234 |
| to close | -0.08% | 48% | 233 |
| Middle 50% of ASMB reactions | -1.63% to +1.05% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 236 |
Half of all Assembly Biosciences, Inc. news events land between -1.63% and +1.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ASMB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 15 | +0.20% | 53% | -1.98% |
| Rating reiterations | 32 | -0.08% | 47% | +0.77% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ASMB ranks against every other measured name →
That’s how ASMB usually reacts — get an email when it moves on news →Email me when ASMB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ASMB's baseline. Nothing else.
Recent ASMB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 | Press release | GlobeNewswire | +0.91% | +0.71% | |
| Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference | Press release | GlobeNewswire | +1.33% | -3.34% | |
| Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program | Press release | GlobeNewswire | +0.03% | -7.77% | |
| Form S-8 ASSEMBLY BIOSCIENCES, | SEC filing · Form S-8 | SEC EDGAR | +1.62% | +1.54% | |
| Form 8-K/A ASSEMBLY BIOSCIENCES, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | -7.86% | |
| Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates | Press release | GlobeNewswire | +1.56% | +9.54% | |
| Form 10-Q ASSEMBLY BIOSCIENCES, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.56% | +9.54% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | +9.54% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -3.90% | |
| Assembly Biosciences Announces Upcoming Investor Conference Presentations | Press release | GlobeNewswire | -1.73% | -0.25% | |
| Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -1.15% | -4.23% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -1.15% | -4.23% | |
| Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases | Press release | GlobeNewswire | +6.61% | -0.94% | |
| Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +6.61% | -0.94% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +6.61% | -0.94% | |
| Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 | Press release | GlobeNewswire | -0.88% | +3.73% | |
| Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference | Press release | GlobeNewswire | +1.90% | +3.29% | |
| Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights | Press release | GlobeNewswire | +0.25% | -2.62% | |
| Form 10-Q ASSEMBLY BIOSCIENCES, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.25% | -2.62% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | -2.62% | |
| Form ARS ASSEMBLY BIOSCIENCES, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.00% | |
| Form DEF 14A ASSEMBLY BIOSCIENCES, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.00% | |
| Form DEFA14A ASSEMBLY BIOSCIENCES, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.00% | |
| Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 | Press release | GlobeNewswire | +0.00% | +2.58% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | +2.74% | |
| Form EFFECT ASSEMBLY BIOSCIENCES, | SEC filing · Form EFFECT | SEC EDGAR | -2.23% | -4.31% | |
| Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | -4.21% | -5.54% | |
| Form 10-K ASSEMBLY BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.21% | -5.54% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -4.21% | -5.54% | |
| Form S-3 ASSEMBLY BIOSCIENCES, | SEC filing · Form S-3 | SEC EDGAR | -4.21% | -5.54% | |
| Form S-8 ASSEMBLY BIOSCIENCES, | SEC filing · Form S-8 | SEC EDGAR | -4.21% | -5.54% | |
| Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re | Press release | GlobeNewswire | -0.10% | -1.44% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | -1.44% | |
| Form EFFECT ASSEMBLY BIOSCIENCES, | SEC filing · Form EFFECT | SEC EDGAR | -0.09% | +0.52% | |
| Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates | Press release | GlobeNewswire | -2.40% | +3.18% | |
| Form 10-Q ASSEMBLY BIOSCIENCES, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.40% | +3.18% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -2.40% | +3.18% | |
| Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® | Press release | GlobeNewswire | +2.85% | +1.00% | |
| Assembly Biosciences Announces Upcoming Investor Conference Participation | Press release | GlobeNewswire | +0.87% | +2.60% | |
| Form S-3 ASSEMBLY BIOSCIENCES, | SEC filing · Form S-3 | SEC EDGAR | -1.39% | +1.17% | |
| Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe | Press release | GlobeNewswire | -0.96% | -1.67% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | — | |
| Assembly Biosciences Announces Pricing of $175 Million in Equity Financings | Press release | GlobeNewswire | -2.91% | +9.95% | |
| Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes | Press release | GlobeNewswire | -2.91% | +9.95% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -2.91% | +9.95% | |
| Form S-3MEF ASSEMBLY BIOSCIENCES, | SEC filing · Form S-3MEF | SEC EDGAR | -2.91% | +9.95% | |
| Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus | Press release | GlobeNewswire | +0.00% | +10.93% | |
| Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates | Press release | GlobeNewswire | +0.00% | +10.93% | |
| Form 10-Q ASSEMBLY BIOSCIENCES, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +10.93% | |
| Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +10.93% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ASMB section they belong to.
Where else ASMB is measured.
ASMB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RESTORBIO (TORC) | 238 | -0.17% | 46% |
| Retractable Technologies, Inc. (RVP) | 237 | 0.00% | 45% |
| Fortress Biotech, Inc. (FBIO) | 235 | -0.68% | 37% |
| Rockwell Medical, Inc. (RMTI) | 235 | +0.40% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Assembly Biosciences, Inc.'s median reaction calculated?
Every labeled ASMB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 236 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of ASMB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ASMB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.